WallStSmart

Quest Diagnostics Incorporated (DGX)vsIQVIA Holdings Inc (IQV)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

IQVIA Holdings Inc generates 46% more annual revenue ($17.31B vs $11.84B). DGX leads profitability with a 9.5% profit margin vs 8.1%. IQV appears more attractively valued with a PEG of 0.98. DGX earns a higher WallStSmart Score of 64/100 (C+).

DGX

Buy

64

out of 100

Grade: C+

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 5/9Altman Z: 2.37

IQV

Buy

59

out of 100

Grade: C

Growth: 5.3Profit: 6.5Value: 6.0Quality: 3.0
Piotroski: 2/9Altman Z: 1.23
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DGXSignificantly Overvalued (-87.2%)

Margin of Safety

-87.2%

Fair Value

$111.82

Current Price

$250.81

$138.99 premium

UndervaluedFair: $111.82Overvalued
IQVUndervalued (+13.7%)

Margin of Safety

+13.7%

Fair Value

$205.31

Current Price

$258.44

$53.13 discount

UndervaluedFair: $205.31Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DGX1 strengths · Avg: 8.0/10
EPS GrowthGrowth
28.7%8/10

Earnings expanding 28.7% YoY

IQV2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.3%9/10

Every $100 of equity generates 22 in profit

PEG RatioValuation
0.988/10

Growing faster than its price suggests

Areas to Watch

DGX1 concerns · Avg: 4.0/10
PEG RatioValuation
1.584/10

Expensive relative to growth rate

IQV4 concerns · Avg: 2.5/10
P/E RatioValuation
33.5x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.232/10

Distress zone — elevated risk

Debt/EquityHealth
2.631/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : DGX

The strongest argument for DGX centers on EPS Growth.

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.98 suggests the stock is reasonably priced for its growth.

Bear Case : DGX

The primary concerns for DGX are PEG Ratio.

Bear Case : IQV

The primary concerns for IQV are P/E Ratio, Piotroski F-Score, Altman Z-Score. Debt-to-equity of 2.63 is elevated, increasing financial risk.

Key Dynamics to Monitor

IQV carries more volatility with a beta of 1.17 — expect wider price swings.

DGX is growing revenue faster at 10.0% — sustainability is the question.

DGX generates stronger free cash flow (574M), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DGX scores higher overall (64/100 vs 59/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Quest Diagnostics Incorporated

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

Want to dig deeper into these stocks?